Severe cutaneous adverse reactions to drugs - Relevant aspects to diagnosis and treatment - Part I: Anaphylaxis and anaphylactoid reactions, erythroderma and the clinical spectrum of Stevens-Johnson syndrome & toxic epidermal necrolysis (Lyell's disease);Reações cutâneas graves adversas a drogas - Aspectos relevantes ao diagnóstico e ao tratamento - Parte I - Anafilaxia e reações anafilactóides, eritrodermias e o espectro clínico da síndrome de Stevens-Johnson & necrólise epidérmica tóxica (Doença de Lyell)

Anais Brasileiros de Dermatologia

Volumn 79, Issue 4, 2004, Pages 471-488

  Criado, Paulo Ricardo ^a,b,c,g   Ramos, Rodrigo De Oliveira ^b,c   Criado, Roberta Fachini Jardim ^a,b,c,d   Gonçalves, Andréia Christina ^f   Vasconcellos, Cidia ^d,e  

^a UEPA   (Brazil)

^b HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^c Clinical Medicine   (Brazil)

^d FACULDADE DE MEDICINA DO ABC   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f ESTÁCIO DE SÁ UNIVERSITY   (Brazil)

^g Sao Paulo Hosp Serv Pub Estadual ^*  (Brazil)

Author keywords

Anaphylaxis; Drug hypersensitivity; Epidermal necrolysis, toxic; Eryithema multiforme; Pharmaceutical preparations adverse effects; Stevens Johnson syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALLOPURINOL; AMINOPENICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; BETA LACTAM ANTIBIOTIC; BLOOD DERIVATIVE; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CHLORHEXIDINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRONE; ENZYME; FLUORESCEIN; HEPARIN; IMMUNOGLOBULIN; IODINATED CONTRAST MEDIUM; PHENOBARBITAL; PHENYLBUTAZONE; PIROXICAM; SILVER NITRATE; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; UNINDEXED DRUG; VACCINE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; BURN CARE UNIT; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ERYTHRODERMA; GRAFT VERSUS HOST REACTION; HOSPITALIZATION; HUMAN; INFECTION; INTENSIVE CARE; INTENSIVE CARE UNIT; LABORATORY TEST; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SEVERE CUTANEOUS ADVERSE REACTION TO DRUGS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYMPTOMATOLOGY; TOXIC EPIDERMAL NECROLYSIS;

EID: 4444350755     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0365-05962004000400009     Document Type: Review

References (39)

1. Weiss ME, Adkinson Jr NF. Diagnostic testing for drug hypersensitivity. Immunol Allergy Clin N Am 1998;18(4):731-44.
2. Bigby M, Jick S, Jick H, Arndt K. Drug-induced reactions: a report from the Boston collaborative drug surveillance program on 15.438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358-63.
3. Djien V, Bocquet H, Dupuy A, Revuz J, Roujeau J-C. Sémilogie et marqueurs de sévérité des toxidermies érythé mateuses. Ann Dermatol Venereol 1999;126:247-50.
4. Roujeau J-C, Stern RS. Severe adverse cutaneous reaction to drugs. N Engl J Med 1994;10:1272-85.
5. Leape LL, Brennan TA, Laird N, Lawthers AG, Localio AR, Barnes BA et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991;324:377-84.
6. Alanko K, Stubb S, Kauppinen K. Cutaneous drug reactions: clinical types and causative agents: a five-year survey of in-patients (1981-1985). Acta Derm Venereol (Stockh) 1989;69:223-6.
7. The Diagnosis and management of anaphylaxis. Joint Task Force on Practice Parameters of American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Concil of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1998; 101: s465-528.
8. Rusznak C, Peebles Jr RS. Anaphylaxis and anaphylactoid reactions. A guide to prevention, recognition and emergent treatment. Postgrad Med 2002;111:101-14.
9. Rohte MJ, Bialy BA, Grant-Kels JM. Erythroderma. Dermatol Clin 2000; 18: 405-15.
10. Vasconcellos C, Domingues PP, Aoki V, Miyake RK, Savaia N, Martins JEC. Erythroderma: analysis of 247 cases. Rev Saúde Pública 1995;29:177-82.
11. Gentile H, Lodin A, Skog E. Dermatitis exfoliativa: cases admitted in the decade 1948-1957 to the dermatological clinic, Karolinska Sjukhuset, Stockholm, Sweden. Acta Derm Venereol 1956;38:296.
12. Sehgal VN, Srivastava G. Exfoliative dermatitis: a prospective study of 80 patients. Dermatologica 1986;173:278-84.
13. Freedberg IM. Exfoliative Dermatitis, in Freedberg IM, Eisen AZ, Wolff K, Austin KF, Goldsmith LA, Katz S, Fitzpatrick TB. Dermatology in General Medicine. 5th ed. New York: Mc Graw-Hill, 1999. p. 534-7.
14. Revuz JE, Roujeau JC. Advances in toxic epidermal necrolysis. Semin Cutan Med. Surg 1996;15:258-66.
15. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000;18:
16. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983;8:763-75.
17. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: Study of sixty cases. J Am Acad Dermatol 1985;13:623-35.
18. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme major and Stevens-Johnson syndrome are clinically different disorders with distinct etiologies. Arch Dermatol 1995;131:539-45.
19. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J-C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993;129:92-6.
20. Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Jonhson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-73.
21. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Frechet ML, Gerre JP. Toxic epidermal necrolysis (Lyell Syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
22. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-7.
23. Roujeau JC, Chosidow O, Saiag P, Gillaume JC. Toxic epidermal necrolysis (Lyell Syndrome). J Am Acad Dermatol 1990;23:1039-58.
24. Brett As, Phillips D, Lynn AW. Intravenous immunoglobulin therapy for Stevens-Johnson syndrome. South Med Journal 2001;94(3):342-3.
25. Patterson R, Miller M, Kaplan M, Doan T, Brown J, Detjen P et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994;73:27-34.
26. Ghislain P-D, Roujeau J-C. Treatment of severe drug reactions: Stevens-Johnson syndrome, Toxic Epidermal Necrolysis and Hypersensitivity syndrome. Dermatology Online Journal [serial on line] 2002;8(1):5. Available at: http://dermatology.cdlib.org/DOJvo18num1/reviews/drugrxn/ghislain.html
27. Criado PR, Vasconcellos C, Criado RFJ, Sittart JAS. O espectro do eritema multiforme (eritema multiforme minor e major) e o espectro da Síndrome de Stevens-Johnson e da Necrólise Epidérmica Tóxica (síndrome de Lyell). Rev Bras Clin Terap 2002;28(3):113-21.
28. Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schöpf E. Low N-acetylanting capacity in patiets with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Exp Dermatol 1995;4:313-6.
29. Wolkestein P, Carrière V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, et al. A slow acetylator genotype is a risk factor for sulphonamide-indiced Toxic Epidermal Necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995;5:255.
30. Mockenhaupt M, Norgauer J. Cutaneous Adverse Drug Reactions. Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. ACI International 2002;14(4):143-50.
31. Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E et al. Delayed reactions to drugs show levels of perform, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109:115-61.
32. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrilha J. Increased interleukin 10, tumor necrosis factor a, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol 2002;47:58-62.
33. Chosidow O, Bourgault-Villada I, Roujeau JC. Drug rashes. What are the targets of cell-mediated cytotoxicity? Arch Dermatol 1994;130:627-9.
34. Prins C, Kerdel FA, Padilla S, Hunziker T, Chimenti S, Viard I et al. Treatment of Toxic Epidermal Necrolysis with High-Dose Intravenous Immunoglobulins. Arch Dermatol 2003;139:26-32.
35. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003;139:33-36.
36. Wolff K, Tappeiner G. Treatment of toxic epidermal necrolysis. Arch Dermatol 2003;139:85-6.
37. Mockenhaupt M, Schöpf E. Epidemiology of Drug-induced severe skin reactions. Sem Cutan Med Surg 1996;15(4):236-43.
38. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau J-C. Correlations Between Clinical Patterns and Causes of Erythema Multiforme Majus, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. Arch Dermatol 2002;138:1019-1024.
39. Roujeau J-C, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.